Cyclerion sets Sept 4, 2026 record date for CVR distribution in Korsana merger

Cyclerion Therapeutics, Inc.

Record date of Sept 4, 2026 fixed for contingent value rights (CVRs) to holders of common stock and Series A Preferred.
CVRs issued in connection with planned merger with Korsana Biosciences; merger still pending shareholder approval.
CVR payment date, number of CVRs, and terms (transferability, listing) not yet disclosed.
Merger completion remains subject to closing conditions, including obtaining required approvals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.